Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -105.22 Million CHF | -133.4% |
| 2022 | -43.36 Million CHF | -5.09% |
| 2021 | -41.26 Million CHF | -38.15% |
| 2020 | -29.87 Million CHF | -38.04% |
| 2019 | -21.63 Million CHF | 25.93% |
| 2018 | -29.21 Million CHF | 25.05% |
| 2017 | -38.97 Million CHF | -8.36% |
| 2016 | -35.97 Million CHF | -12.79% |
| 2015 | -31.89 Million CHF | -49.36% |
| 2014 | -21.35 Million CHF | -35.73% |
| 2013 | -15.73 Million CHF | 1.71% |
| 2012 | -16 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -79.64 Million CHF | -100.0% |
| 2023 Q4 | -10.78 Million CHF | 0.0% |
| 2023 Q3 | -10.78 Million CHF | 86.46% |
| 2023 FY | -101.21 Million CHF | -133.4% |
| 2023 Q1 | -39.82 Million CHF | -174.46% |
| 2022 FY | -43.36 Million CHF | -5.09% |
| 2022 Q3 | -7.25 Million CHF | 74.86% |
| 2022 Q4 | -14.5 Million CHF | -100.0% |
| 2022 Q2 | -28.85 Million CHF | -100.0% |
| 2022 Q1 | -14.42 Million CHF | 9.21% |
| 2021 Q1 | -12.68 Million CHF | 22.42% |
| 2021 Q2 | -25.37 Million CHF | -100.0% |
| 2021 FY | -41.26 Million CHF | -38.15% |
| 2021 Q3 | -7.94 Million CHF | 68.68% |
| 2021 Q4 | -15.89 Million CHF | -100.0% |
| 2020 Q2 | -13.51 Million CHF | -100.0% |
| 2020 Q4 | -16.35 Million CHF | -100.0% |
| 2020 Q1 | -6.75 Million CHF | 40.32% |
| 2020 Q3 | -8.17 Million CHF | 39.5% |
| 2020 FY | -29.87 Million CHF | -38.04% |
| 2019 Q4 | -11.32 Million CHF | -100.0% |
| 2019 Q3 | -5.66 Million CHF | 45.1% |
| 2019 Q2 | -10.31 Million CHF | -100.0% |
| 2019 Q1 | -5.15 Million CHF | 29.01% |
| 2019 FY | -21.63 Million CHF | 25.93% |
| 2018 Q2 | -7.34 Million CHF | 0.0% |
| 2018 Q3 | -7.26 Million CHF | 1.08% |
| 2018 FY | -29.21 Million CHF | 25.05% |
| 2018 Q4 | -7.26 Million CHF | 0.0% |
| 2018 Q1 | -7.34 Million CHF | 21.19% |
| 2017 Q3 | -9.31 Million CHF | 8.39% |
| 2017 Q4 | -9.31 Million CHF | 0.0% |
| 2017 FY | -38.97 Million CHF | -8.36% |
| 2017 Q2 | -10.17 Million CHF | 0.0% |
| 2017 Q1 | -10.17 Million CHF | -18.67% |
| 2016 Q3 | -8.57 Million CHF | 8.96% |
| 2016 FY | -35.97 Million CHF | -12.79% |
| 2016 Q1 | -9.41 Million CHF | -26.87% |
| 2016 Q2 | -9.41 Million CHF | 0.0% |
| 2016 Q4 | -8.57 Million CHF | 0.0% |
| 2015 Q1 | -8.52 Million CHF | -54.53% |
| 2015 Q4 | -7.42 Million CHF | 0.0% |
| 2015 Q3 | -7.42 Million CHF | 12.95% |
| 2015 FY | -31.89 Million CHF | -49.36% |
| 2015 Q2 | -8.52 Million CHF | 0.0% |
| 2014 FY | -21.35 Million CHF | -35.73% |
| 2014 Q3 | -5.51 Million CHF | -6.91% |
| 2014 Q1 | -5.15 Million CHF | -41.25% |
| 2014 Q2 | -5.15 Million CHF | 0.0% |
| 2014 Q4 | -5.51 Million CHF | 0.0% |
| 2013 Q4 | -3.65 Million CHF | 0.0% |
| 2013 FY | -15.73 Million CHF | 1.71% |
| 2013 Q1 | -4.21 Million CHF | -47.87% |
| 2013 Q2 | -4.21 Million CHF | 0.0% |
| 2013 Q3 | -3.65 Million CHF | 13.29% |
| 2012 Q4 | -2.84 Million CHF | 0.0% |
| 2012 Q3 | -2.84 Million CHF | 0.0% |
| 2012 FY | -16 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5991.586% |
| CSL Limited | 2.64 Billion USD | 103.983% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -40.375% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1500.177% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -38388.892% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 298.625% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 261.561% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -5680.158% |
| Mesoblast Limited | -87.95 Million USD | -19.639% |
| Marizyme, Inc. | -65.34 Million USD | -61.032% |
| Genus plc | 7.9 Million USD | 1432.018% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -866.139% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2736.193% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -1089.839% |
| ContraFect Corporation | -65.15 Million USD | -61.511% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -2053.664% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -36.48 Million USD | -188.413% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1205.627% |
| MultiCell Technologies, Inc. | -380.07 USD | -27686747.16% |
| Accustem Sciences Inc. | -3.74 Million USD | -2708.8% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -103.57% |
| EV Biologics, Inc. | -1.26 Million USD | -8204.52% |
| Q BioMed Inc. | -2.05 Million USD | -5027.906% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2718.896% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -4319.788% |
| Biomind Labs Inc. | -1.21 Million USD | -8565.713% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1231.496% |
| Skye Bioscience, Inc. | -37.64 Million USD | -179.532% |
| SQZ Biotechnologies Company | -79.46 Million USD | -32.424% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -702553.579% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1406.972% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -3538.142% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -563.011% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -16539.506% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -897.624% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -4749.697% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1708.919% |
| GB Sciences, Inc. | -1.36 Million USD | -7627.927% |
| Alpha Cognition Inc. | -13.77 Million USD | -664.051% |
| argenx SE | -295.05 Million USD | 64.335% |
| HST Global, Inc. | -146.21 Thousand USD | -71871.411% |
| Halberd Corporation | -79.67 Thousand USD | -131971.64% |
| Enzolytics Inc. | -2.17 Million USD | -4734.062% |
| Resverlogix Corp. | -3.61 Million USD | -2814.942% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -3218.036% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -68.101% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -76.189% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 107476.939% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -3292.562% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1619.647% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -5298.459% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2548.618% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -3377.353% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1540.711% |
| ONE Bio Corp. | 8.67 Million USD | 1312.794% |
| Zenith Capital Corp. | -10.59 Million USD | -893.105% |
| Genscript Biotech Corporation | -95.47 Million USD | -10.214% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -452655.357% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2438.134% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -174003.802% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5148.048% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -5896.76% |
| Agentix Corp. | -1.37 Million USD | -7557.441% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.3 Million USD | -3081.637% |
| Helix BioMedix, Inc. | -1.05 Million USD | -9864.367% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2655.418% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1140.476% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -23741.593% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7779.808% |
| LadRx Corporation | 400.44 Thousand USD | 26378.247% |
| Cell Source, Inc. | -5.32 Million USD | -1877.546% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -25227.249% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10381.248% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10381.248% |
| NovAccess Global Inc. | -4.76 Million USD | -2106.443% |
| Affymax, Inc. | -14.42 Million USD | -629.544% |
| Itoco Inc. | -1.86 Million USD | -5530.267% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -2268.679% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -6204.937% |
| CytoDyn Inc. | -49.84 Million USD | -111.13% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -133046.154% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -46027.552% |
| Qrons Inc. | -789.34 Thousand USD | -13231.197% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -11076.437% |
| SYBLEU INC | -180.3 Thousand USD | -58262.21% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4940.49% |
| Rebus Holdings, Inc. | -1.02 Million USD | -10216.608% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -6424.895% |
| Mobile Lads Corp. | -2.26 Million USD | -4549.396% |
| International Stem Cell Corporation | -131 Thousand USD | -80227.786% |
| Bioxytran, Inc. | -4.28 Million USD | -2358.63% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -193792.615% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -4058.859% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -118.9% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4877.739% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -13375.625% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -3221.635% |
| Neutra Corp. | -233.46 Thousand USD | -44972.88% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -418.601% |
| PureTech Health plc | -65.69 Million USD | -60.174% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -394.812% |
| IXICO plc | -1.17 Million USD | -8832.886% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -960.032% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -84.199% |
| CSL Limited | 2.64 Billion USD | 103.983% |
| Cellectis S.A. | -103.17 Million USD | -1.992% |